Kyprolis® extends progression free survival over Velcade in head-to-head trial

Data from an interim analysis of the international Phase III trial ENDEAVOUR, a head-to-head comparison of Kyprolis (carfilzomib) and low-dose dexamethasone versus Velcade and low-dose dexamethasone for relapsed myeloma patients, have recently been released by the pharmaceutical company, Amgen. They showed that patients treated with Kyprolis and dexamethasone had twice the progression free survival of…

Details